Brought to you by 
Pfizer and GlaxoSmithKline set up HIV joint venture
11 Jun 2014
Executive Summary
In a move that gives them 19% of the global HIV market, GlaxoSmithKline and Pfizer have set up a joint venture to focus on 17 of their marketed drugs and pipeline compounds for this infectious disease. Together the assets have an estimated book value of £250mm ($373mm). Some analysts say the yet-unnamed new entity may likely be spun off or sold in the future.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer and GlaxoSmithKline set up HIV joint venture
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice